Cardiff Oncology's PLK1 Inhibitor Onvansertib Shows Promise in CMML Trial and Advances Toward Phase III in Colorectal Cancer
核心洞察
Cardiff Oncology's onvansertib demonstrated preliminary efficacy in approximately 40% of chronic myelomonocytic leukemia (搜索) patients in a Phase 1 trial, with one patient achieving optimal marrow response at the 9 mg/m² dose.
The PLK1 (搜索) inhibitor showed remarkable overall response rates of 77% and median progression-free survival of 14.9 months in bevacizumab-naïve metastatic colorectal cancer (搜索) patients, compared to standard of care rates of 20% and 7 months respectively.
Cardiff is preparing for a registrational Phase III trial in metastatic colorectal cancer (搜索) expected to begin in Q1 2026, with FDA Fast Track designation already awarded.
Cardiff Oncology announced clinical data from an investigator-sponsored Phase 1 trial demonstrating that onvansertib, its PLK1 (搜索) inhibitor, showed preliminary efficacy in approximately 40% of patients with chronic myelomonocytic leukemia (搜索) (CMML). The data, presented at the 67th American Society of Hematology Annual Meeting, revealed that one patient achieved an optimal marrow response at the 9 mg/m² dose in the nine-patient dose escalation study.
The CMML trial results validate onvansertib's single agent activity across both hematologic and solid tumors, building on previously announced data from investigator-sponsored trials in small cell lung cancer (搜索). However, Cardiff Oncology is not currently planning to develop onvansertib for CMML, focusing instead on its lead indication in metastatic colorectal cancer (搜索).
Breakthrough Results in Colorectal Cancer
Cardiff's primary development focus centers on onvansertib's combination therapy for RAS-mutated metastatic colorectal cancer (搜索) (mCRC), where the drug has demonstrated remarkable clinical activity. In prior trials, onvansertib combined with bevacizumab and chemotherapy achieved an overall response rate (ORR) of 77% and median progression-free survival (PFS) of 14.9 months in bevacizumab-naïve patients in the second-line setting.
These results represent a substantial improvement over standard of care, which typically achieves a 20% ORR and PFS of 7 months in second-line treatment. The dose-dependent response has been observed at both 20 mg and 30 mg doses of onvansertib when combined with bevacizumab and chemotherapy, consistently producing superior outcomes compared to standard treatment protocols.
Addressing Unmet Medical Need
Metastatic colorectal cancer (搜索) represents a significant unmet medical need, particularly in the metastatic setting where mortality remains high and approved therapies provide progression-free survival of around a year or less. Despite being the third or fourth most common cancer globally and in the United States, with an estimated 154,000 new cases of colorectal cancer expected in 2025, the field has seen limited innovation over the past 20 years.
The addressable market for onvansertib in the current mCRC setting encompasses approximately 30,000 patients in the United States and about 84,000 in the developed world, representing roughly 19% of the total colorectal cancer population.
Regulatory Progress and Development Timeline
Cardiff has received FDA Fast Track designation for onvansertib and is working closely with the FDA to design a registrational Phase III trial. The company expects to begin this registrational trial in Q1 2026, designed to satisfy requirements for both accelerated and full approval. If Phase III results replicate the Phase II findings, Cardiff anticipates FDA approval following achievement of the study's accelerated endpoints, with registrational data expected by 2029.
The adverse event profile for combination onvansertib has been similar to standard of care, with the drug demonstrating relative tolerability across trials. Onvansertib's mechanism of action as a highly specific PLK1 (搜索) inhibitor with low off-target binding affinity contributes to its favorable safety profile while inhibiting the angiogenesis cascade.
Strategic Partnerships and Financial Position
Cardiff has developed strategic relationships, particularly with Pfizer, which initially invested $15 million in the company through its Breakthrough Growth Initiative program in 2021. This partnership includes a Pfizer representative on Cardiff's Scientific Advisory Board and provides Pfizer with right of first access to data prior to publication. In 2023, Pfizer Ignite's clinical development infrastructure began providing expertise to run onvansertib's mCRC trial.
The company maintains a robust financial position with over $60 million in cash at the beginning of Q4 2025 and a cash burn rate of approximately $40 million per year, providing sufficient funds to support operations into 2027. Cardiff also has access to an at-the-market facility with Jefferies to augment registered offerings at low cost.
Intellectual Property and Future Outlook
Cardiff's intellectual property portfolio addresses multiple indications and combination therapies, with patents extending until 2043 and eligibility for five years of patent term extension. The company expects further updates in the new year as Phase II mCRC data continue to mature and following meetings with the FDA to finalize the registrational trial design.